New hope for hard-to-treat lymphoma: triple-drug combo enters human testing

NCT ID NCT05182957

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen May 06, 2026 · Last updated Jun 15, 2026 · Updated 8 times

Summary

This study is testing whether a combination of three drugs (an immunotherapy called anti-PD-1 plus lenalidomide and azacitidine) can shrink tumors or stop them from growing in people with a rare type of blood cancer called peripheral T-cell lymphoma that has not responded to standard treatments. About 31 adults with measurable disease will receive the treatment and be followed for up to 3 years to see how many achieve a complete or partial response. The goal is to find a more effective option for this difficult-to-treat condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA